Allergan Aesthetics Redefines Skin Quality Communication with Launch of Skin Quality Index
The research revealed a meaningful disconnect in how patients and providers describe skin quality. While patients tended to use consistent language among themselves, terminology often diverged when communicating with providers – creating potential barriers during consultations and treatment planning. The SQI addresses these inconsistencies by introducing 15 consensus terms and definitions across four core dimensions of skin health, creating a shared language for more effective dialogue. Clearer terminology can help providers better understand patient goals, support more informed treatment planning, and ultimately contribute to improved aesthetic outcomes. The framework also helps patients develop a clearer understanding of their own skin quality, empowering them to take a more active role in discussions about their care.
"The Skin Quality Index is a groundbreaking innovation that represents a paradigm shift in how we approach patient consultations and treatment planning in aesthetics," said Dr. Shannon Humphrey, board-certified dermatologist and primary investigator of the study. "The data clearly demonstrated the need for a standardized vocabulary. By providing a shared language, the Skin Quality Index empowers patients to articulate their concerns more effectively, enables physicians to better understand and address those concerns, and ultimately will lead to more personalized and successful treatment outcomes."
"Advancing the science of aesthetic medicine requires a deeper understanding of how patients and providers talk about skin quality," said Dr. Stephanie Manson Brown, vice president, head of clinical development, scientific innovation and skincare research & development, Allergan Aesthetics. "The Skin Quality Index reflects our commitment to deepening that understanding by establishing a shared language that can support more meaningful research, inform innovation, and further the field of aesthetic medicine."
To support the introduction of the SQI, Allergan Aesthetics has launched educational resources for both patients and providers, including a dedicated microsite and an interactive quiz developed in partnership with New Beauty.
The research, published in Dermatologic Surgery, followed a three-phase methodical approach to define how skin quality is described across medical specialties and diverse patient populations. Phase one analyzed over 900 aesthetic medicine publications spanning more than two decades, representing the largest and most comprehensive review of skin quality terminology to date. Phase two convened U.S. advisory boards of health care providers to establish consensus definitions. Phase three included qualitative patient focus groups and quantitative surveys of more than 200 aesthetic providers and over 1,000 patients to evaluate how terminology varies in real-world conversations.
About Allergan Aesthetics
At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. Our goal is to consistently provide our customers with innovation, education, exceptional service, and a commitment to excellence, all with a personal touch. For more information, visit www.allerganaesthetics.com.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas including immunology, neuroscience and oncology – and products and services in our Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on LinkedIn, Facebook, Instagram, X (formerly Twitter), and YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions and uses of future or conditional verbs, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those expressed or implied in the forward-looking statements. Such risks and uncertainties include, but are not limited to, challenges to intellectual property, competition from other products, difficulties inherent in the research and development process, adverse litigation or government action, and changes to laws and regulations applicable to our industry. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2024 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation, and specifically declines, to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.
Media:
Adelle Infante
[email protected]
Investors:
Liz Shea
[email protected]
SOURCE AbbVie